Discovery and Optimization
of 1‑Phenoxy-2-aminoindanes
as Potent, Selective, and Orally Bioavailable Inhibitors of the Na<sup>+</sup>/H<sup>+</sup> Exchanger Type 3 (NHE3)
The design, synthesis, and structure–activity
relationship
of 1-phenoxy-2-aminoindanes as inhibitors of the Na<sup>+</sup>/H<sup>+</sup> exchanger type 3 (NHE3) are described based on a hit from
high-throughput screening (HTS). The chemical optimization resulted
in the discovery of potent, selective, and orally bioavailable NHE3
inhibitors with <b>13d</b> as best compound, showing high in
vitro permeability and lacking CYP2D6 inhibition
as main optimization parameters. Aligning 1-phenoxy-2-aminoindanes
onto the X-ray structure of <b>13d</b> then provided 3D-QSAR
models for NHE3 inhibition capturing guidelines for optimization.
These models showed good correlation coefficients and allowed for
activity estimation. In silico ADMET models for Caco-2 permeability
and CYP2D6 inhibition were also successfully applied for this series.
Moreover, docking into the CYP2D6 X-ray structure provided a reliable
alignment for 3D-QSAR models. Finally <b>13d</b>, renamed as
SAR197, was characterized in vitro and by in vivo pharmacokinetic
(PK) and pharmacological studies to unveil its potential for reduction
of obstructive sleep apneas